Chlamydia Infection Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Type of Infections, By End User, By Region and Competition, 2020-2030F

Description

The Global Chlamydia Infection Diagnostics Market was valued at USD 721.33 million in 2024 and is projected to reach USD 1031.67 million by 2030, growing at a CAGR of 6.12% during the forecast period. Chlamydia trachomatis, the bacterium responsible for chlamydia infections, is one of the most widespread causes of sexually transmitted infections (STIs) globally. Due to its often asymptomatic nature, chlamydia frequently goes undiagnosed, leading to complications such as infertility, pelvic inflammatory disease, and increased vulnerability to other infections. As awareness grows and the global burden of STIs rises-particularly among sexually active individuals aged 15 to 24-demand for timely, accurate diagnostics has increased. The market has responded with technological innovations that enhance accessibility and accuracy, such as nucleic acid amplification tests (NAATs), which are recognized for their high sensitivity. Despite the reliance on centralized laboratories, ongoing efforts are focused on improving test turnaround and expanding reach through point-of-care technologies, supporting broader public health strategies to contain the infection.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 721.33 Million
Market Size 2030	USD 1031.67 Million
CAGR 2025-2030	6.12%
Fastest Growing Segment	Hospitals
Largest Market	North America

Key Market Drivers

Rising Prevalence of Chlamydia Infections is Driving Chlamydia Infection Diagnostics Market

The increasing global incidence of chlamydia infections is a major force behind the growth of the diagnostics market. As one of the most commonly reported STIs worldwide, chlamydia poses a significant health risk-particularly among adolescents and young adults who often lack awareness or access to regular testing. The asymptomatic nature of the infection makes it difficult to detect early, increasing the likelihood of long-term reproductive health complications such as infertility and ectopic pregnancies. The heightened focus on routine screening, particularly in high-risk populations, has accelerated the demand for diagnostic tools capable of delivering rapid, accurate results. This has led to the development and deployment of innovative testing methods, bolstering early intervention efforts and supporting global STI control initiatives. Educational campaigns and increased testing infrastructure are further reinforcing the demand for reliable chlamydia diagnostic solutions.

Key Market Challenges

Underdiagnosis and Lack of Awareness

A persistent challenge in the chlamydia diagnostics market is the widespread underdiagnosis of the infection, largely due to its asymptomatic presentation in the majority of cases. Without noticeable symptoms, many individuals remain unaware they are infected and do not seek testing, allowing the disease to spread undetected. This issue is compounded by limited public knowledge about STI risks, as well as cultural stigma surrounding sexual health, which deters open discussion and testing. In some regions, inadequate healthcare infrastructure and insufficient provider emphasis on STI screening further restrict access to diagnostics. These systemic and societal barriers contribute to a gap between infection rates and testing volumes, limiting early treatment and increasing the burden of long-term health complications.

Key Market Trends

Technological Advancements

Advancements in molecular diagnostics are significantly shaping the chlamydia diagnostics market. NAATs, including PCR and LAMP, have become the benchmark for detecting the genetic material of Chlamydia trachomatis, offering unparalleled sensitivity and specificity. These methods enable early detection, which is critical for timely treatment and preventing transmission. Furthermore, smartphone-integrated diagnostic platforms are emerging as accessible, user-friendly tools that facilitate at-home testing. These innovations empower individuals to screen for STIs with greater privacy and convenience. In parallel, serological and antibody-based assays are being utilized to detect historical infections, contributing to epidemiological tracking and broader public health insights. The integration of nucleic acid and serological tests is enhancing diagnostic capability, paving the way for more comprehensive infection profiling and treatment planning.

Key Market Players

F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Hologic, Inc.
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc
Quidel Corporation
DiaSorin SpA
AstraZeneca
Teva Pharmaceutical Industries Limited
bioMerieux SA

Report Scope:

In this report, the Global Chlamydia Infection Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chlamydia Infection Diagnostics Market, By Test Type:

Culture Test
Nucleic Acid Amplification Test (NAAT)
Direct Fluorescent Antibody Test
Serology Test
Other

Chlamydia Infection Diagnostics Market, By Type of Infections:

Genital Chlamydia Infection
Rectal Chlamydia Infection
Ocular Chlamydia Infection

Chlamydia Infection Diagnostics Market, By End User:

Hospitals
Specialty Clinics
Diagnostics Centre

Chlamydia Infection Diagnostics Market, By Region:

North America
Asia-Pacific
Europe
Middle East & Africa
South America

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chlamydia Infection Diagnostics Market.

Available Customizations:

Global Chlamydia Infection Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chlamydia Infection Diagnostics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Test Type (Culture Test, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Test and Other)
- 5.2.2. By Type of Infections (Genital Chlamydia Infection, Rectal Chlamydia Infection, Ocular Chlamydia Infection)
- 5.2.3. By End User (Hospitals, Specialty Clinics, Diagnostics Centre)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
5.3. Market Map
- 5.3.1. By Test Type
- 5.3.2. By Type of Infections
- 5.3.3. By End User
- 5.3.4. By Region

6. North America Chlamydia Infection Diagnostics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Test Type
- 6.2.2. By Type of Infections
- 6.2.3. By End User
- 6.2.4. By Country
  - 6.2.4.1. United States Chlamydia Infection Diagnostics Market Outlook
    - 6.2.4.1.1. Market Size & Forecast
    - 6.2.4.1.1.1. By Value
    - 6.2.4.1.2. Market Share & Forecast
    - 6.2.4.1.2.1. By Test Type
    - 6.2.4.1.2.2. By Type of Infections
    - 6.2.4.1.2.3. By End User
  - 6.2.4.2. Canada Chlamydia Infection Diagnostics Market Outlook
    - 6.2.4.2.1. Market Size & Forecast
    - 6.2.4.2.1.1. By Value
    - 6.2.4.2.2. Market Share & Forecast
    - 6.2.4.2.2.1. By Test Type
    - 6.2.4.2.2.2. By Type of Infections
    - 6.2.4.2.2.3. By End User
  - 6.2.4.3. Mexico Chlamydia Infection Diagnostics Market Outlook
    - 6.2.4.3.1. Market Size & Forecast
    - 6.2.4.3.1.1. By Value
    - 6.2.4.3.2. Market Share & Forecast
    - 6.2.4.3.2.1. By Test
    - 6.2.4.3.2.2. By Type of Infections
    - 6.2.4.3.2.3. By End User

7. Europe Chlamydia Infection Diagnostics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Test Type
- 7.2.2. By Type of Infections
- 7.2.3. By End User
- 7.2.4. By Country
  - 7.2.4.1. France Chlamydia Infection Diagnostics Market Outlook
    - 7.2.4.1.1. Market Size & Forecast
    - 7.2.4.1.1.1. By Value
    - 7.2.4.1.2. Market Share & Forecast
    - 7.2.4.1.2.1. By Test Type
    - 7.2.4.1.2.2. By Type of Infections
    - 7.2.4.1.2.3. By End User
  - 7.2.4.2. Germany Chlamydia Infection Diagnostics Market Outlook
    - 7.2.4.2.1. Market Size & Forecast
    - 7.2.4.2.1.1. By Value
    - 7.2.4.2.2. Market Share & Forecast
    - 7.2.4.2.2.1. By Test Type
    - 7.2.4.2.2.2. By Type of Infections
    - 7.2.4.2.2.3. By End User
  - 7.2.4.3. United Kingdom Chlamydia Infection Diagnostics Market Outlook
    - 7.2.4.3.1. Market Size & Forecast
    - 7.2.4.3.1.1. By Value
    - 7.2.4.3.2. Market Share & Forecast
    - 7.2.4.3.2.1. By Test Type
    - 7.2.4.3.2.2. By Type of Infections
    - 7.2.4.3.2.3. By End User
  - 7.2.4.4. Italy Chlamydia Infection Diagnostics Market Outlook
    - 7.2.4.4.1. Market Size & Forecast
    - 7.2.4.4.1.1. By Value
    - 7.2.4.4.2. Market Share & Forecast
    - 7.2.4.4.2.1. By Test Type
    - 7.2.4.4.2.2. By Type of Infections
    - 7.2.4.4.2.3. By End User
  - 7.2.4.5. Spain Chlamydia Infection Diagnostics Market Outlook
    - 7.2.4.5.1. Market Size & Forecast
    - 7.2.4.5.1.1. By Value
    - 7.2.4.5.2. Market Share & Forecast
    - 7.2.4.5.2.1. By Test Type
    - 7.2.4.5.2.2. By Type of Infections
    - 7.2.4.5.2.3. By End User

8. Asia Pacific Chlamydia Infection Diagnostics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Test Type
- 8.2.2. By Type of Infections
- 8.2.3. By End User
- 8.2.4. By Country
  - 8.2.4.1. China Chlamydia Infection Diagnostics Market Outlook
    - 8.2.4.1.1. Market Size & Forecast
    - 8.2.4.1.1.1. By Value
    - 8.2.4.1.2. Market Share & Forecast
    - 8.2.4.1.2.1. By Test Type
    - 8.2.4.1.2.2. By Type of Infections
    - 8.2.4.1.2.3. By End User
  - 8.2.4.2. India Chlamydia Infection Diagnostics Market Outlook
    - 8.2.4.2.1. Market Size & Forecast
    - 8.2.4.2.1.1. By Value
    - 8.2.4.2.2. Market Share & Forecast
    - 8.2.4.2.2.1. By Test Type
    - 8.2.4.2.2.2. By Type of Infections
    - 8.2.4.2.2.3. By End User
  - 8.2.4.3. South Korea Chlamydia Infection Diagnostics Market Outlook
    - 8.2.4.3.1. Market Size & Forecast
    - 8.2.4.3.1.1. By Value
    - 8.2.4.3.2. Market Share & Forecast
    - 8.2.4.3.2.1. By Test Type
    - 8.2.4.3.2.2. By Type of Infections
    - 8.2.4.3.2.3. By End User
  - 8.2.4.4. Japan Chlamydia Infection Diagnostics Market Outlook
    - 8.2.4.4.1. Market Size & Forecast
    - 8.2.4.4.1.1. By Value
    - 8.2.4.4.2. Market Share & Forecast
    - 8.2.4.4.2.1. By Test Type
    - 8.2.4.4.2.2. By Type of Infections
    - 8.2.4.4.2.3. By End User
  - 8.2.4.5. Australia Chlamydia Infection Diagnostics Market Outlook
    - 8.2.4.5.1. Market Size & Forecast
    - 8.2.4.5.1.1. By Value
    - 8.2.4.5.2. Market Share & Forecast
    - 8.2.4.5.2.1. By Test Type
    - 8.2.4.5.2.2. By Type of Infections
    - 8.2.4.5.2.3. By End User

9. South America Chlamydia Infection Diagnostics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Type of Infections
- 9.2.3. By End User
- 9.2.4. By Country
  - 9.2.4.1. Brazil Chlamydia Infection Diagnostics Market Outlook
    - 9.2.4.1.1. Market Size & Forecast
    - 9.2.4.1.1.1. By Value
    - 9.2.4.1.2. Market Share & Forecast
    - 9.2.4.1.2.1. By Test Type
    - 9.2.4.1.2.2. By Type of Infections
    - 9.2.4.1.2.3. By End User
  - 9.2.4.2. Argentina Chlamydia Infection Diagnostics Market Outlook
    - 9.2.4.2.1. Market Size & Forecast
    - 9.2.4.2.1.1. By Value
    - 9.2.4.2.2. Market Share & Forecast
    - 9.2.4.2.2.1. By Test Type
    - 9.2.4.2.2.2. By Type of Infections
    - 9.2.4.2.2.3. By End User
  - 9.2.4.3. Colombia Chlamydia Infection Diagnostics Market Outlook
    - 9.2.4.3.1. Market Size & Forecast
    - 9.2.4.3.1.1. By Value
    - 9.2.4.3.2. Market Share & Forecast
    - 9.2.4.3.2.1. By Test Type
    - 9.2.4.3.2.2. By Type of Infections
    - 9.2.4.3.2.3. By End User

10. Middle East & Africa Chlamydia Infection Diagnostics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Type of Infections
- 10.2.3. By End User
- 10.2.4. By Country
  - 10.2.4.1. South Africa Chlamydia Infection Diagnostics Market Outlook
    - 10.2.4.1.1. Market Size & Forecast
    - 10.2.4.1.1.1. By Value
    - 10.2.4.1.2. Market Share & Forecast
    - 10.2.4.1.2.1. By Test Type
    - 10.2.4.1.2.2. By Type of Infections
    - 10.2.4.1.2.3. By End User
  - 10.2.4.2. Saudi Arabia Chlamydia Infection Diagnostics Market Outlook
    - 10.2.4.2.1. Market Size & Forecast
    - 10.2.4.2.1.1. By Value
    - 10.2.4.2.2. Market Share & Forecast
    - 10.2.4.2.2.1. By Test Type
    - 10.2.4.2.2.2. By Type of Infections
    - 10.2.4.2.2.3. By End User
  - 10.2.4.3. UAE Chlamydia Infection Diagnostics Market Outlook
    - 10.2.4.3.1. Market Size & Forecast
    - 10.2.4.3.1.1. By Value
    - 10.2.4.3.2. Market Share & Forecast
    - 10.2.4.3.2.1. By Test Type
    - 10.2.4.3.2.2. By Type of Infections
    - 10.2.4.3.2.3. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. Competitive Landscape

13.1. F. Hoffmann-La Roche Ltd.
13.2. Abbott Laboratories
13.3. Hologic, Inc.
13.4. Becton, Dickinson and Company
13.5. Bio-Rad Laboratories, Inc
13.6. Quidel Corporation
13.7. DiaSorin SpA
13.8. AstraZeneca
13.9. Teva Pharmaceutical Industries Limited
13.10. bioMerieux SA